keyword
MENU ▼
Read by QxMD icon Read
search

Vegf eye

keyword
https://www.readbyqxmd.com/read/29451077/intravitreal-aflibercept-versus-ranibizumab-for-wet-age-related-macular-degeneration-a-cost-effectiveness-analysis
#1
Luis Hernandez, Tereza Lanitis, Clifford Cele, Hector Toro-Diaz, Andrea Gibson, Andreas Kuznik
BACKGROUND: Age-related macular degeneration (AMD) is the leading cause of vision loss in the United States. The most severe vision loss occurs in patients with neovascular AMD, known as wet AMD (wAMD). The most commonly used antivascular endothelial growth factor (VEGF) therapies approved by the FDA to treat patients with wAMD are ranibizumab, 0.5 mg administered by intravitreal injection once a month (approximately every 28 days), and intravitreal aflibercept injection (IAI), 2 mg every 4 weeks (monthly) for the first 12 weeks (3 months), followed by IAI 2 mg once every 8 weeks (2 months)...
February 16, 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29450540/endocan-blockade-suppresses-experimental-ocular-neovascularization-in-mice
#2
Ting Su, Yisheng Zhong, Anna M Demetriades, Jikui Shen, Ailing Sui, Yiyun Yao, Yushuo Gao, Yanji Zhu, Xi Shen, Bing Xie
Purpose: Ocular neovascularization (NV) is a pathologic process characterized by the proliferation and infiltration of various types of cells such as RPE, glial, and endothelial cells, which interact with proangiogenic factors and inflammatory cytokines. Endocan is known to be enriched in retinal endothelial tip cells under hypoxia, but the effect of endocan on ocular NV progression is largely unknown. In this study, we investigated the role of endocan in the ocular NV pathologic process and the possible mechanisms involved...
February 1, 2018: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/29450400/incidence-of-ocular-hypertension-after-intravitreal-injection-of-anti-vegf-agents-in-the-treatment-of-neovascular-amd
#3
Andreea Moraru, Gabriela Pînzaru, Anca Moţoc, Dănuţ Costin, Daniel Brănişteanu
Purpose. The assessment of the incidence of ocular hypertension over a period of 1 year in patients treated with multiple intravitreal injections of anti-VEGF agents for neovascular AMD. Methods. The study comprised 58 eyes diagnosed with neovascular age-related macular degeneration and receiving PRN intravitreal treatment with anti-VEGF agents (bevacizumab or aflibercept). The follow-up period was 1 year. Intraocular pressure was measured by using the Goldmann applanation tonometry before the intravitreal injection, at 24 hours after the administration of the anti-VEGF agent and at 1 and 4 weeks...
July 2017: Romanian Journal of Ophthalmology
https://www.readbyqxmd.com/read/29443034/subretinal-transplantation-of-human-embryonic-stem-cell-derived-retinal-pigment-epithelial-cells-into-a-large-eyed-model-of-geographic-atrophy
#4
Sandra Petrus-Reurer, Hammurabi Bartuma, Monica Aronsson, Sofie Westman, Fredrik Lanner, Anders Kvanta
Geographic atrophy (GA), the late stage of dry age-related macular degeneration is characterized by loss of the retinal pigment epithelial (RPE) layer, which leads to subsequent degeneration of vital retinal structures (e.g., photoreceptors) causing severe vision impairment. Similarly, RPE-loss and decrease in visual acuity is seen in long-term follow up of patients with advanced wet age-related macular degeneration (AMD) receiving intravitreal anti-vascular endothelial growth factor (VEGF) treatment. Therefore, on the one hand, it is fundamental to efficiently derive RPE cells from an unlimited source that could serve as replacement therapy...
January 22, 2018: Journal of Visualized Experiments: JoVE
https://www.readbyqxmd.com/read/29439828/consistent-long-term-therapy-of-neovascular-age-related-macular-degeneration-managed-by-50-or-more-anti-vegf-injections-using-a-treat-extend-stop-protocol
#5
Sean D Adrean, Siyang Chaili, Hema Ramkumar, Ash Pirouz, Scott Grant
PURPOSE: To examine the clinical results for patients with neovascular age-related macular degeneration (nAMD) who were managed with a treat-extend-stop (TES) protocol and received 50 or more injections of anti-vascular endothelial growth factor (VEGF) agents. DESIGN: Retrospective case study. PARTICIPANTS: Data for patients from a private retina practice meeting the following criteria were included: diagnosis of nAMD and having received 50 or more intravitreal injections of anti-VEGF agents...
February 10, 2018: Ophthalmology
https://www.readbyqxmd.com/read/29435587/a-disease-associated-microrna-cluster-links-inflammatory-pathways-and-an-altered-composition-of-leukocyte-subsets-to-noninfectious-uveitis
#6
Fleurieke H Verhagen, Cornelis P J Bekker, Marzia Rossato, Sanne Hiddingh, Lieuwe de Vries, Abhinandan Devaprasad, Aridaman Pandit, Jeannette Ossewaarde-van Norel, Ninette Ten Dam, Maartje C A Moret-Pot, Saskia M Imhof, Joke H de Boer, Timothy R D J Radstake, Jonas J W Kuiper
Purpose: The cause of noninfectious uveitis (NIU) is poorly understood but is considered to be mediated by a complex interplay between genetic, environmental, and-relatively unexplored-epigenetic factors. MicroRNAs (miRNAs) are noncoding small RNAs that are important epigenetic regulators implicated in pathologic signaling. Therefore, we mapped the circulating miRNA-ome of NIU patients and studied miRNA perturbations within the broader context of the immune system. Methods: We designed a strategy to robustly identify changes in the miRNA profiles of two independent cohorts totaling 54 untreated patients with active and eye-restricted disease and 26 age-matched controls...
February 1, 2018: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/29426292/pre-treatment-clinical-features-in-central-retinal-vein-occlusion-that-predict-visual-outcome-following-intravitreal-ranibizumab
#7
Kerr Brogan, Monica Precup, Amanda Rodger, David Young, David Francis Gilmour
BACKGROUND: Predicting how patients with central retinal vein occlusion (CRVO) will respond to intravitreal anti-VEGF is challenging. The purpose of this study was to identify pre-treatment clinical features in CRVO that predict visual acuity (VA) following intravitreal ranibizumab. METHODS: Medical records, fundus images and optical coherence tomography (OCT) scans of treatment naïve patients with CRVO receiving PRN intravitreal ranibizumab were retrospectively reviewed...
February 9, 2018: BMC Ophthalmology
https://www.readbyqxmd.com/read/29404860/ranibizumab-versus-aflibercept-for-the-treatment-of-vascularized-pigment-epithelium-detachment-due-to-age-related-macular-degeneration
#8
Alexandros Rouvas, Irini Chatziralli, Angeliki Androu, Panagiota Mpougatsou, Dimitrios Alonistiotis, Maria Douvali, Stamatina A Kabanarou, Panagiotis Theodossiadis
PURPOSE: To compare the efficacy and safety of two intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents, ranibizumab and aflibercept, for the treatment of vascularized pigment epithelium detachment (vPED) due to age-related macular degeneration (AMD) in a follow-up time of 12 months. METHODS: Participants in this study were 71 patients (71 eyes) with vPED due to AMD, who were treated with intravitreal 0.5 mg ranibizumab (n = 38) or 2.0 mg aflibercept (n = 33) and had at least 12-month follow-up...
February 5, 2018: International Ophthalmology
https://www.readbyqxmd.com/read/29402873/repeated-dexamethasone-intravitreal-implant-for-the-treatment-of-diabetic-macular-oedema-unresponsive-to-anti-vegf-therapy-outcome-and-predictive-sd-oct-features
#9
Katja Hatz, Andreas Ebneter, Cengiz Tuerksever, Christian Pruente, Martin Zinkernagel
PURPOSE: To investigate dexamethasone intravitreal implant 0.7 mg (DEX implant) for the treatment of diabetic macular oedema (DME) refractory to anti-vascular endothelial growth factor (anti-VEGF) therapy and evaluate predictive factors. METHODS: Two-centre retrospective interventional case series, including 40 eyes of 31 patients treated with DEX implant for at least 2 consecutive cycles. RESULTS: Mean ± SD intervals from implantation to recurrence in the first (4...
February 2, 2018: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/29398697/clinical-pharmacology-of-intravitreal-anti-vegf-drugs
#10
REVIEW
Stefano Fogli, Marzia Del Re, Eleonora Rofi, Chiara Posarelli, Michele Figus, Romano Danesi
Clinical efficacy of intravitreal anti-VEGF drugs has been widely demonstrated in several angiogenesis-driven eye diseases including diabetic macular edema and the neovascular form of age-related macular degeneration. Pegaptanib, ranibizumab, and aflibercept have been approved for use in the eye, whereas bevacizumab is widely used by ophthalmologists to treat patients "off-label". These drugs are active in the nanomolar to picomolar range; however, caution is required when establishing the rank order of affinity and potency due to in vitro inter-experimental variation...
February 5, 2018: Eye
https://www.readbyqxmd.com/read/29397436/the-fate-of-eyes-with-wet-amd-beyond-four-years-of-anti-vegf-therapy
#11
Justus G Garweg, Johanna J Zirpel, Christin Gerhardt, Isabel B Pfister
PURPOSE: Real-life studies on long-term functional outcome of anti-VEGF treatment for wet age-related macular degeneration (wAMD) are limited. We therefore assessed the 10-year outcomes in our patients. METHODS: In this retrospective study, all patients with newly diagnosed wAMD that had received minimally three intravitreal injections between 2007 and 2012 and a follow-up of ≥48 months were included. Primary outcome measure was the evolution of best-corrected visual acuity (BCVA) over time...
February 3, 2018: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29392309/sphingosine-kinase-2-modulates-retinal-neovascularization-in-the-mouse-model-of-oxygen-induced-retinopathy
#12
Jeanette Eresch, Martin Stumpf, Alexander Koch, Rajkumar Vutukuri, Nerea Ferreirós, Yannick Schreiber, Katrin Schröder, Kavi Devraj, Rüdiger Popp, Lars-Olof Hattenbach, Josef Pfeilschifter, Waltraud Pfeilschifter
Purpose: Neovascularization is a major cause of blindness in various ocular diseases. Bioactive sphingosine 1-phosphate (S1P), synthesized by two sphingosine kinases (Sphk1, Sphk2), emerged as a key player in a multitude of cellular processes, including cell survival, proliferation, inflammation, migration, and angiogenesis. We investigated the role of Sphk2, S1P, and S1P receptors (S1PR) during retinal neovascularization using the oxygen-induced retinopathy mouse model (OIR). Methods: Sphk2 overexpressing (tgSphk2) and Sphk2 knockout (Sphk2-/-) mice were used in the OIR model, exposed to 75% O2 over 5 days from postnatal day (P)7 to 12 to initiate vessel regression...
February 1, 2018: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/29390407/influence-of-vitreomacular-interface-on-anti-vascular-endothelial-growth-factor-treatment-outcomes-in-neovascular-age-related-macular-degeneration-a-moose-compliant-meta-analysis
#13
Meng Gao, LiMei Liu, XiDa Liang, YanPing Yu, XinXin Liu, Wu Liu
The aim of the study was to evaluate the influence of vitreomacular interface configuration on treatment outcomes after intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for neovascular age-related macular degeneration (AMD).The Pubmed, Embase, and Cochrane Central Register of Controlled Trials databases were searched to identify relevant prospective or retrospective studies that evaluate the influence of vitreomacular adhesion (VMA) or vitreomacular traction (VMT) on functional and anatomical outcomes in neovascular AMD patients treated with anti-VEGF agents...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29382038/extended-duration-vascular-endothelial-growth-factor-inhibition-in-the-eye-failures-successes-and-future-possibilities
#14
REVIEW
Michael W Stewart
Vascular endothelial growth factor (VEGF) plays a pivotal role in the development of neovascularization and edema from several common chorioretinal vascular conditions. The intravitreally injected drugs (aflibercept, bevacizumab, conbercept, pegaptanib, and ranibizumab) used to treat these conditions improve the visual acuity and macular morphology in most patients. Monthly or bimonthly injections were administered in the phase III pivotal trials but physicians usually individualize therapy with pro re nata (PRN) or treat and extend regimens...
January 27, 2018: Pharmaceutics
https://www.readbyqxmd.com/read/29378530/comparison-of-efficacy-between-anti-vascular-endothelial-growth-factor-vegf-and-laser-treatment-in-type-1-and-threshold-retinopathy-of-prematurity-rop
#15
Zijing Li, Yichi Zhang, Yunru Liao, Rui Zeng, Peng Zeng, Yuqing Lan
BACKGROUND: Retinopathy of Prematurity (ROP) is one of the most common causes of childhood blindness worldwide. Comparisons of anti-VEGF and laser treatments in ROP are relatively lacking, and the data are scattered and limited. The objective of this meta-analysis is to compare the efficacy of both treatments in type-1 and threshold ROP. METHODS: A comprehensive literature search on ROP treatment was conducted using PubMed and Embase up to March 2017 in all languages...
January 30, 2018: BMC Ophthalmology
https://www.readbyqxmd.com/read/29376143/bevacizumab-injection-in-patients-with-neovascular-age-related-macular-degeneration-increases-angiogenic-biomarkers
#16
Thiago Cabral, Luiz H Lima, Luiz Guilherme M Mello, Júlia Polido, Éverton P Correa, Akiyoshi Oshima, Jimmy Duong, Pedro Serracarbassa, Caio V Regatieri, Vinit B Mahajan, Rubens Belfort
Purpose: To evaluate the expression of 19 angiogenic biomarkers in the aqueous humor before and after intravitreal bevacizumab injection (IVB) in eyes with neovascular age-related macular degeneration (AMD). Design: Prospective, noncomparative, interventional case series. Participants: Twenty-three eyes of 23 treatment-naïve patients with choroidal neovascularization (CNV) secondary to neovascular AMD. Methods: Eyes were diagnosed with CNV secondary to neovascular AMD and were treated with 3 monthly IVBs...
January 2018: Ophthalmology Retina
https://www.readbyqxmd.com/read/29364731/yc-1-inhibits-vegf-and-inflammatory-mediators-expression-on-experimental-central-retinal-vein-occlusion-in-rhesus-monkey
#17
Zhipeng Yan, Jianbin An, Qingli Shang, Nalei Zhou, Jingxue Ma
PURPOSES: To investigate the therapeutic potential of YC-1 for experimental central retinal vein occlusion (CRVO) of rhesus monkey. METHODS: Six adult rhesus monkeys were recruited in this study. Laser-induced CRVO was established in both eyes of all subjects. Intravitreal injection of YC-1 90 μl (200 μM with 0.01% dimethyl sulfoxide (DMSO) as vehicle) was administrated in right eye and 0.01% DMSO 90 μl in left eye respectively at 1 week after CRVO established...
January 24, 2018: Current Eye Research
https://www.readbyqxmd.com/read/29361327/comparison-of-macular-parameters-after-femtosecond-laser-assisted-and-conventional-cataract-surgery-in-age-related-macular-degeneration
#18
Tim J Enz, Livia Faes, Lucas M Bachmann, Michael A Thiel, Jeremy P Howell, Sophie C Boehni, Mario Bittner, Martin K Schmid
PURPOSE: To evaluate differences in postoperative central macular thickness, central macular volume, corrected distance visual acuity (CDVA), and number of intravitreal anti-vascular endothelial growth factor (VEGF) injections between conventional and femtosecond laser-assisted cataract surgery in wet age-related macular degeneration (AMD). SETTING: Tertiary referral center, Lucerne, Switzerland. DESIGN: Retrospective case series. METHODS: Consecutive patients with AMD and cataract were enrolled between January 2010 and December 2015...
January 17, 2018: Journal of Cataract and Refractive Surgery
https://www.readbyqxmd.com/read/29348424/intraocular-inflammatory-cytokines-in-patients-with-neovascular-age-related-macular-degeneration-before-and-after-initiation-of-intravitreal-injection-of-anti-vegf-inhibitor
#19
Tomohito Sato, Masaru Takeuchi, Yoko Karasawa, Toshio Enoki, Masataka Ito
Age-related macular degeneration (AMD) is a cause of blindness in people older than 50 years. Accumulating evidence indicates the involvement of systemic and local inflammation in the pathogenesis and progression of AMD. Aflibercept is an anti-vascular endothelial growth factor (VEGF) inhibitor, and intravitreal injection of aflibercept (IVA) is the approved treatments of neovascular AMD (nAMD), but the effect on inflammatory response remains unclear. The aim of our study was to investigate the profiles of inflammatory cytokines in the aqueous humor of nAMD patients before and after initiation of IVA...
January 18, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29339088/retinal-neuronal-cell-loss-prevents-abnormal-retinal-vascular-growth-in-a-rat-model-of-retinopathy-of-prematurity
#20
Ayuki Nakano, Daiki Asano, Ryo Kondo, Asami Mori, Shiho Arima, Hiroko Ushikubo, Kenji Sakamoto, Tohru Nagamitsu, Kunio Ishii, Tsutomu Nakahara
A short-term blockade of the vascular endothelial growth factor (VEGF)-mediated pathway in neonatal rats results in formation of severe retinopathy of prematurity (ROP)-like retinal blood vessels. The present study aimed to examine the role of retinal neurons in the formation of abnormal retinal blood vessels. Newborn rats were treated subcutaneously with the VEGF receptor tyrosine kinase inhibitor, KRN633 (10 mg/kg), or its vehicle (0.5% methylcellulose in water) on postnatal day (P) 7 and P8. To induce excitotoxic loss of retinal neurons, N-methyl-D-aspartic acid (NMDA) was injected into the vitreous chamber of the eye on P9...
January 12, 2018: Experimental Eye Research
keyword
keyword
4979
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"